Covered recipient · General Payments record
YASSMIN SHARIFF
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2023–2024
$407.29
- Reported across 19 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $389.80 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $236.28 | 9 |
| Lilly USA, LLC | $85.48 | 5 |
| GlaxoSmithKline, LLC. | $19.28 | 1 |
| Exact Sciences Corporation | $18.02 | 1 |
| ABBVIE INC. | $15.94 | 1 |
| Amgen Inc. | $14.80 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $15.94 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106074158 | CMS |
| Amgen Inc. | $14.80 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116112148 | CMS |
| Exact Sciences Corporation | $18.02 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114891000 | CMS |
| GlaxoSmithKline, LLC. | $19.28 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116270710 | CMS |
| Lilly USA, LLC | $16.62 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135509478 | CMS |
| Lilly USA, LLC | $18.46 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135442769 | CMS |
| Lilly USA, LLC | $18.23 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135504056 | CMS |
| Lilly USA, LLC | $16.65 | 06/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135504058 | CMS |
| Lilly USA, LLC | $15.52 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135504060 | CMS |
| Novo Nordisk Inc | $21.47 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096899564 | CMS |
| Novo Nordisk Inc | $15.07 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096859912 | CMS |
| Novo Nordisk Inc | $24.09 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097172407 | CMS |
| Novo Nordisk Inc | $15.45 | 06/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096936497 | CMS |
| Novo Nordisk Inc | $16.49 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096785129 | CMS |
| Novo Nordisk Inc | $15.25 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097499547 | CMS |
| Novo Nordisk Inc | $105.41 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097776639 | CMS |
| Novo Nordisk Inc | $13.37 | 09/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097703266 | CMS |
| Novo Nordisk Inc | $9.68 | 12/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097200063 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.